Head-to-head evidence
CJ-30061 vs OLOMAX
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: Angiotensin II receptor / Calcium channel / HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline
CJ-30061
Developed by HK inno.N Corporation
NCT03639480 · Phase 3 · status unknown
The trial is randomized, blinded, and actively controlled, and measures blood pressure and LDL cholesterol, both accepted clinical endpoints for these conditions. However, results have not been posted yet, so whether the triple combination outperformed the two-drug regimens is unknown.
OLOMAX
Developed by Daewoong Pharmaceutical
NCT01764295 · Phase 3 · completed
The study was randomized and triple-blinded, with active and placebo comparator groups and an estimated enrollment of 150 participants. Its primary measures were changes in LDL cholesterol and diastolic blood pressure, and because the registry provides no results, it is not possible to determine whether either primary endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CJ-30061's landscape · OLOMAX's landscape